Northwest Biotherapeutics: Comments on FDA Guidance for Use of Contemporaneous External Controls; Importance for DCVax-L
The FDA just issued new guidance on the use of contemporaneous external controls in clinical trials. Hedge funds who are massively short Northwest Biotherapeutics stock have falsely argued that the FDA cannot and will not accept contemporaneous external controls as used in the phase 3 DCVax-L clinical trial in glioblastoma. It is their fervent hope […]
